By Connor Hart
Artiva Biotherapeutics named Subhashis Banerjee as its chief medical officer, succeeding Thorsten Graef, who will continue to serve the company as a strategic adviser.
Banerjee is a trained rheumatologist and immunologist with more than two decades of clinical development experience in autoimmune diseases, the San Diego-based company said Tuesday.
His appointment will help the company progress the clinical development of its treatment of B-cell driven autoimmune diseases, Chief Executive Fred Aslan said.
Prior to joining Artiva, Banerjee helmed Bristol Myers Squibb's rheumatology and dermatology global development arm. Previously, he held an executive position at Vyne Therapeutics.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 08, 2025 16:57 ET (20:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.